Epitalon (Epithalon)

What it is

Epitalon, also spelled epithalon, is a synthetic peptide made of four building blocks: alanine, glutamic acid, aspartic acid and glycine. It was built according to the amino acid composition of epithalamin, an extract from the pineal gland of cattle. The pineal gland is the small gland in the brain that also produces melatonin.

It was developed at the Institute of Bioregulation and Gerontology in St. Petersburg. Behind it is the idea of bioregulators: the body supposedly uses short peptides as control signals that tell a tissue to work again as it did in younger years. Not an active substance that forces something, more a conductor who sets a new tempo. This is an elegant concept, and it comes largely from the same school as the substances themselves.

How it is supposed to work

At the ends of our chromosomes sit protective caps, the telomeres, similar to the plastic tips on shoelaces. With every cell division they become a little shorter. When they are too short, the cell stops dividing and ages. The enzyme telomerase can lengthen the caps again, but in most adult body cells it is practically switched off.

Epitalon is supposed to switch the gene for the catalytic subunit of telomerase, hTERT, back on. More telomerase, longer caps, the clock is turned back a little. A second mechanism described is an influence on melatonin production and the day-night rhythm, plus antioxidant effects. A 2025 review summarizes that in the laboratory epitalon acts on melatonin synthesis, immune messengers and several enzymes, and leaves open whether these are all the mechanisms.

What was shown in the laboratory and in animals

The strongest finding is the cell culture. In fetal human connective tissue cells, which do not produce telomerase on their own, epitalon triggered the formation of the catalytic subunit, enzyme activity rose, and the telomeres became longer. In a follow-up experiment, untreated lung fibroblasts stopped dividing at passage 34. With epitalon, the telomeres regained the length of early passages, and the cells managed 10 additional divisions up to passage 44.

In animals, the results are more mixed than they are often portrayed. In female mice with 54 animals per group, epitalon did not change mean lifespan. Maximum lifespan was 12.3 percent higher, that of the last 10 percent of survivors 13.3 percent higher. Chromosome damage in the bone marrow fell by 17.1 percent, leukemias occurred less often, and the total number of tumors remained the same. In cancer-prone mice carrying the breast cancer gene HER-2/neu, it extended mean lifespan by 13.5 percent.

Sleep and user reports

Because epitalon derives from the pineal gland, sleep is considered its most noticeable side. Users report that the first thing they notice is better sleep, often already in the first weeks, and with it more energy and better mood. In a study with the extract epithalamin, the daily rhythm of melatonin production normalized in older heart patients.

That is a real, pleasant effect when it occurs. But it is not proof that the cellular clock is being turned back in the background. Sleep and telomeres are two different construction sites, and only the first is one you can feel.

What the studies show

Khavinson 2003 and 2004 — telomeres in cell culture

The original paper treated telomerase-negative fetal human fibroblasts with epitalon. Expression of the catalytic telomerase subunit, enzyme activity and telomere length were measured; all three rose. The 2004 follow-up experiment showed that treated cells managed 10 additional passages beyond their natural division limit. Both papers come from the developer group, small series of experiments without independent replication at the time.

Al-Dulaimi 2025 — the independent confirmation

The London group studied two breast cancer cell lines as well as normal epithelial and connective tissue cells. In the normal cells, the telomeres lengthened dose-dependently via hTERT and telomerase. In the cancer cells they also lengthened markedly, but there via an alternative pathway called ALT. This is the most important support for the mechanism so far and at the same time an indication that cancer cells also respond.

Anisimov 2003 — lifespan in mice

From the third month of life until natural death, female mice regularly received epitalon or saline, 54 animals per group. Food intake, body weight and mean lifespan did not change. Maximum lifespan was 12.3 percent higher, leukemias occurred 6.0-fold less often, and overall tumor incidence remained the same.

Korkushko 2006 — twelve years with the extract

Older patients with coronary heart disease and accelerated vascular aging received epithalamin in addition to standard therapy, or standard therapy alone. After 12 years, the number of deaths in the treated group was 28 percent lower, and cardiovascular mortality was halved. In the 2011 analysis there were 39 versus 40 patients. What was tested was the extract, not the tetrapeptide, by the same research group, in very few people.

Where the data stop

The decisive sentence is in a 2026 review: randomized human trials, pharmacokinetic studies or registered clinical trials with epitalon itself have not been published. The tempting long-term data, fewer deaths over 12 years, come from the pineal gland extract epithalamin, from small groups and from a single research school. There is no study in which telomere length was measured in living humans after administration of epitalon and published after peer review.

Then there is the question of what longer telomeres mean at all. Telomeres are only one of many construction sites of aging, alongside mitochondria, inflammation, cellular waste and senescent cells. And very long telomeres are not automatically good, because cells with unlimited capacity to divide are a double-edged sword.

Status, approval and legal

Epitalon is not approved as a medicine in Germany or the EU and is sold as a research peptide over the internet. There is no pharmaceutical quality control for these products; purity and actual content are not assured without analysis. An approval of the tetrapeptide in another country could not be documented in the sources reviewed. On July 23–24, 2026, an FDA expert panel discussed whether epitalon should be permitted for compounded medicines in the US. The FDA’s own reviewers advised against it; the panel nonetheless voted in favor by majority (votes 7:4, 1 abstention). An FDA decision is pending; a formal procedure is unlikely to begin before 2027. In sport, as a non-approved substance, it falls under class S0 of the WADA prohibited list and is banned at all times.

Safety

In the animal studies no harm was noticed; the authors explicitly regard their mouse data as an indication of the safety of long-term administration in mice. In humans, the safety of epitalon has not been systematically studied, neither in the short nor in the long term. User reports describe the peptide as well tolerated, but that does not replace a study. The fundamental concern is the mechanism itself: the same telomerase that keeps aging cells able to divide for longer makes cancer cells immortal. In the 2025 cell study, the telomeres also lengthened in cancer cells. Anyone who has or has had cancer, or is pregnant or breastfeeding, has no data basis for use.

Sources

• Khavinson et al., Bull Exp Biol Med 2003 (telomerase in fibroblasts)
• Khavinson et al., Bull Exp Biol Med 2004 (Hayflick limit)
• Al-Dulaimi et al., Biogerontology 2025 (independent replication)
• Anisimov et al., Biogerontology 2003 (lifespan in mice)
• Anisimov et al., Bull Exp Biol Med 2002 (HER-2/neu mice)
• Korkushko et al., Bull Exp Biol Med 2006 (epithalamin (pineal gland extract), not epitalon; 12 years)
• Korkushko et al., Bull Exp Biol Med 2011 (epithalamin (pineal gland extract), not epitalon; melatonin rhythm)
• Araj et al., Int J Mol Sci 2025 (review)
• Jain et al., Preprints 2026 (review, not peer-reviewed)
• McDermott Will & Schulte, PCAC vote 2026